Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Acer Therapeutics Inc. (ACER)

0.75   -0.022 (-2.85%) 03-24 16:00
Open: 0.7701 Pre. Close: 0.772
High: 0.8 Low: 0.743
Volume: 121,293 Market Cap: 17(M)

Technical analysis

as of: 2023-03-24 4:23:44 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.98     One year: 2.74
Support: Support1: 0.65    Support2: 0.54
Resistance: Resistance1: 1.7    Resistance2: 2.34
Pivot: 1.32
Moving Average: MA(5): 0.78     MA(20): 1.5
MA(100): 2.01     MA(250): 1.83
MACD: MACD(12,26): -0.4     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 7.6     %D(3): 8.8
RSI: RSI(14): 21.4
52-week: High: 4.55  Low: 0.65
Average Vol(K): 3-Month: 481 (K)  10-Days: 1,069 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ACER ] has closed above bottom band by 19.1%. Bollinger Bands are 79% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.8 - 0.8 0.8 - 0.81
Low: 0.73 - 0.74 0.74 - 0.74
Close: 0.74 - 0.75 0.75 - 0.76

Company Description

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Headline News

Wed, 22 Mar 2023
ACER THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

Wed, 22 Mar 2023
Acer Therapeutics Announces Data Presented at Society for ... - GlobeNewswire

Mon, 20 Mar 2023
Healthcare Stocks Moving Up and Down Monday: LFCR, ACER, INM, GOSS, AZYO, CODX, OMGA, SOPH - InvestorsObserver

Mon, 20 Mar 2023
Why Bed Bath & Beyond Shares Are Trading Lower By Around 24 ... - Benzinga

Fri, 17 Mar 2023
Why Baidu Shares Are Trading Higher By More Than 6%? Here Are ... - Benzinga

Fri, 17 Mar 2023
Crude Oil Down 2%; Enzo Biochem Shares Spike Higher - Acer ... - Benzinga

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 21 (M)
% Held by Insiders 1.069e+007 (%)
% Held by Institutions 18.3 (%)
Shares Short 498 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.37e+007
EPS Est Next Qtl 0
EPS Est This Year -4.87
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -6
Return on Assets (ttm) 603
Return on Equity (ttm) -62.1
Qtrly Rev. Growth 360000
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 1.93846e+006
Qtrly Earnings Growth -0.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow -23 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.65

Stock Dividends

Dividend 0
Forward Dividend 295590
Dividend Yield 0%
Dividend Pay Date 2017-09-20
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.